Huntington's disease: Options for controlling symptoms

Huntingtons disease is an autosomal dominant hereditary neurodegenerative disorder characterised by chorea, disturbed voluntary motor performance, behavioural changes and dementia. Despite the recent discovery of the gene defect (an expanded trinucleotide repeat) and its product huntingtin, no curat...

Full description

Saved in:
Bibliographic Details
Published in:CNS drugs 1999-02, Vol.11 (2), p.105-123
Main Authors: VAN VUGT, J. P. P, ROOS, R. A. C
Format: Article
Language:English
Subjects:
Biological and medical sciences
Medical sciences
Miscellaneous
Neuropharmacology
Pharmacology. Drug treatments
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 123
container_issue 2
container_start_page 105
container_title CNS drugs
container_volume 11
creator VAN VUGT, J. P. P
ROOS, R. A. C
description Huntingtons disease is an autosomal dominant hereditary neurodegenerative disorder characterised by chorea, disturbed voluntary motor performance, behavioural changes and dementia. Despite the recent discovery of the gene defect (an expanded trinucleotide repeat) and its product huntingtin, no curative therapy is available to date. Confronted with genetically determined inevitable functional decline, psychosocial support remains the hallmark in the care for patients and relatives. Pharmacological treatment is limited to reduction of chorea and behavioural disturbances, often at the cost of further impairing voluntary movement and, consequently, functional capacity. Therefore, drug therapy should be highly individualised and generally restricted to patients with severely disabling symptoms.
doi_str_mv 10.2165/00023210-199911020-00003
format article
fullrecord <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_proquest_miscellaneous_19670249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19670249</sourcerecordid><originalsourceid>FETCH-LOGICAL-p213t-7ff6ba414328454570a10ea82b5d484dab47f3b0d4300fb7e046eb233cca6fd83</originalsourceid><addsrcrecordid>eNotzEFLxDAQBeAgCq6r_6EH0VN1JpMmrTdZ1BUW9qLnkraJVNqkdrKH_fcW3dN7PD6eEBnCg0RdPAKAJImQY1VViCAhXyagM7FCNNUykzr_6zI3oMyluGL-XoQirVdCbw8h9eErxXDPWdezs-yesv2U-hg483HO2hjSHIdhURkfxynFka_FhbcDu5tTrsXn68vHZpvv9m_vm-ddPkmklBvvdWMVKpKlKlRhwCI4W8qm6FSpOtso46mBThGAb4wDpV0jidrWat-VtBZ3_7_THH8OjlM99ty6YbDBxQPXWGkDUlULvD1By60d_GxD23M9zf1o52ONBrAgoF-PcVeM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19670249</pqid></control><display><type>article</type><title>Huntington's disease: Options for controlling symptoms</title><source>Springer Nature</source><creator>VAN VUGT, J. P. P ; ROOS, R. A. C</creator><creatorcontrib>VAN VUGT, J. P. P ; ROOS, R. A. C</creatorcontrib><description>Huntingtons disease is an autosomal dominant hereditary neurodegenerative disorder characterised by chorea, disturbed voluntary motor performance, behavioural changes and dementia. Despite the recent discovery of the gene defect (an expanded trinucleotide repeat) and its product huntingtin, no curative therapy is available to date. Confronted with genetically determined inevitable functional decline, psychosocial support remains the hallmark in the care for patients and relatives. Pharmacological treatment is limited to reduction of chorea and behavioural disturbances, often at the cost of further impairing voluntary movement and, consequently, functional capacity. Therefore, drug therapy should be highly individualised and generally restricted to patients with severely disabling symptoms.</description><identifier>ISSN: 1172-7047</identifier><identifier>EISSN: 1179-1934</identifier><identifier>DOI: 10.2165/00023210-199911020-00003</identifier><language>eng</language><publisher>Hong Kong: Adis International</publisher><subject>Biological and medical sciences ; Medical sciences ; Miscellaneous ; Neuropharmacology ; Pharmacology. Drug treatments</subject><ispartof>CNS drugs, 1999-02, Vol.11 (2), p.105-123</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1701530$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>VAN VUGT, J. P. P</creatorcontrib><creatorcontrib>ROOS, R. A. C</creatorcontrib><title>Huntington's disease: Options for controlling symptoms</title><title>CNS drugs</title><description>Huntingtons disease is an autosomal dominant hereditary neurodegenerative disorder characterised by chorea, disturbed voluntary motor performance, behavioural changes and dementia. Despite the recent discovery of the gene defect (an expanded trinucleotide repeat) and its product huntingtin, no curative therapy is available to date. Confronted with genetically determined inevitable functional decline, psychosocial support remains the hallmark in the care for patients and relatives. Pharmacological treatment is limited to reduction of chorea and behavioural disturbances, often at the cost of further impairing voluntary movement and, consequently, functional capacity. Therefore, drug therapy should be highly individualised and generally restricted to patients with severely disabling symptoms.</description><subject>Biological and medical sciences</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><issn>1172-7047</issn><issn>1179-1934</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNotzEFLxDAQBeAgCq6r_6EH0VN1JpMmrTdZ1BUW9qLnkraJVNqkdrKH_fcW3dN7PD6eEBnCg0RdPAKAJImQY1VViCAhXyagM7FCNNUykzr_6zI3oMyluGL-XoQirVdCbw8h9eErxXDPWdezs-yesv2U-hg483HO2hjSHIdhURkfxynFka_FhbcDu5tTrsXn68vHZpvv9m_vm-ddPkmklBvvdWMVKpKlKlRhwCI4W8qm6FSpOtso46mBThGAb4wDpV0jidrWat-VtBZ3_7_THH8OjlM99ty6YbDBxQPXWGkDUlULvD1By60d_GxD23M9zf1o52ONBrAgoF-PcVeM</recordid><startdate>19990201</startdate><enddate>19990201</enddate><creator>VAN VUGT, J. P. P</creator><creator>ROOS, R. A. C</creator><general>Adis International</general><scope>IQODW</scope><scope>7TK</scope></search><sort><creationdate>19990201</creationdate><title>Huntington's disease: Options for controlling symptoms</title><author>VAN VUGT, J. P. P ; ROOS, R. A. C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p213t-7ff6ba414328454570a10ea82b5d484dab47f3b0d4300fb7e046eb233cca6fd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Biological and medical sciences</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VAN VUGT, J. P. P</creatorcontrib><creatorcontrib>ROOS, R. A. C</creatorcontrib><collection>Pascal-Francis</collection><collection>Neurosciences Abstracts</collection><jtitle>CNS drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VAN VUGT, J. P. P</au><au>ROOS, R. A. C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Huntington's disease: Options for controlling symptoms</atitle><jtitle>CNS drugs</jtitle><date>1999-02-01</date><risdate>1999</risdate><volume>11</volume><issue>2</issue><spage>105</spage><epage>123</epage><pages>105-123</pages><issn>1172-7047</issn><eissn>1179-1934</eissn><abstract>Huntingtons disease is an autosomal dominant hereditary neurodegenerative disorder characterised by chorea, disturbed voluntary motor performance, behavioural changes and dementia. Despite the recent discovery of the gene defect (an expanded trinucleotide repeat) and its product huntingtin, no curative therapy is available to date. Confronted with genetically determined inevitable functional decline, psychosocial support remains the hallmark in the care for patients and relatives. Pharmacological treatment is limited to reduction of chorea and behavioural disturbances, often at the cost of further impairing voluntary movement and, consequently, functional capacity. Therefore, drug therapy should be highly individualised and generally restricted to patients with severely disabling symptoms.</abstract><cop>Hong Kong</cop><cop>Auckland</cop><pub>Adis International</pub><doi>10.2165/00023210-199911020-00003</doi><tpages>19</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1172-7047
ispartof CNS drugs, 1999-02, Vol.11 (2), p.105-123
issn 1172-7047
1179-1934
language eng
recordid cdi_proquest_miscellaneous_19670249
source Springer Nature
subjects Biological and medical sciences
Medical sciences
Miscellaneous
Neuropharmacology
Pharmacology. Drug treatments
title Huntington's disease: Options for controlling symptoms
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T10%3A14%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Huntington's%20disease:%20Options%20for%20controlling%20symptoms&rft.jtitle=CNS%20drugs&rft.au=VAN%20VUGT,%20J.%20P.%20P&rft.date=1999-02-01&rft.volume=11&rft.issue=2&rft.spage=105&rft.epage=123&rft.pages=105-123&rft.issn=1172-7047&rft.eissn=1179-1934&rft_id=info:doi/10.2165/00023210-199911020-00003&rft_dat=%3Cproquest_pasca%3E19670249%3C/proquest_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p213t-7ff6ba414328454570a10ea82b5d484dab47f3b0d4300fb7e046eb233cca6fd83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19670249&rft_id=info:pmid/&rfr_iscdi=true